Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICN's PURCHASE OF 6.3% OF HOFFMANN-LaROCHE VOTING STOCK

Executive Summary

ICN's PURCHASE OF 6.3% OF HOFFMANN-LaROCHE VOTING STOCK is an investment of approximately $200 mil. based on current exchange rates and the current per share price of Roche voting stock (300,000 Swiss francs). ICN disclosed the purchase Sept. 22 in a press release in anticipation of its third quarter report. F. Hoffmann-LaRoche, the Swiss parent of the worldwide Roche group, has 16,000 voting shares. The company says that more than 50%, "a clear majority," of the shares are closely held by family members. ICN's purchase gives the California company a holding of about 1,000 shares. The company had cash and marketable securities of about $375 mil. at the end of the second quarter. ICN's investment created an aura of prestige for the California company with the financial press. The affiliation with the Roche name may help ICN's image at a time when news concerning its major product continues to be bleak. ICN's major product in development, ribavirin for AIDS, remains tied up at FDA. ICN has continued to pursue a request for a Treatment IDN for the product; FDA has rejected the request twice. It would be hard to conceive of a more headline-grabbing move in the drug industry with a $200 mil. investment. For the same amount of money, ICN could have purchased only much smaller pieces of major U.S. drug companies -- e.g., about 1.5% of Lilly common or 2.8% of SmithKline. To try to buy more than 5% of a U.S. company, ICN would also have faced U.S. reporting requirements. The company did not have to register its accumulation of Roche with SEC. ICN said it has reported the purchases under Hart-Scott-Rodino. ICN disclosed the purchase with a terse press release, giving full play to the mystery of its intentions. ICN has used an investment in a Swiss drug company previously as a way to raise money. In early March of this year, ICN tied a $40 mil. (60 mil. Swiss franc) convertible bond offer to shares of Ciba-Geigy. In that offering, conducted outside the U.S., ICN said the bonds could be converted into 1.5 mil. shares of ICN stock at $26.14 per share; or 15,000 Ciba-Geigy shares at 4,000 Swiss francs per share; or 750,000 ICN shares and 7,500 Ciba-Geigy shares. In the bond financing, the Ciba-Geigy shares in effect added ballast for the bond purchasers.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel